This study is testing a new treatment called AP01 for people with Progressive Pulmonary Fibrosis (PPF), which is a lung disease that makes it hard to breathe. The study will see if inhaling AP01 is safe and helps people with PPF. There will be 300 people in the study, and they will be given either a high dose of AP01, a low dose, or a placebo. A placebo is something that looks like medicine but doesn’t contain any active ingredients. The study will last for 52 weeks (1 year). Participants must have PPF and meet other health criteria to join. They cannot be currently taking oral pirfenidone or have certain health conditions like liver or kidney problems.
- Duration: 1 year with regular check-ups.
- Eligibility: Must have PPF and meet health criteria.
- Compensation/Risks: Details not provided, check with the study team.
How understandable was the trial content above?
Hard to understand
Easy to understand